462 在ENGOT-EN6-NSGO/GOG-3031/RUBY试验中,与单纯化疗相比,多司他单抗联合化疗治疗原发性晚期/复发性子宫内膜癌患者的无进展生存期2-无进展生存期1

C. Mccourt, G. Ronzino, M. Shahin, Rebecca Kristeleit, L. Willmott, Oleksandr Zub, J. Barlin, L. Gilbert, N. Cloven, Line Bjørge, D. Black, M. Wymenga, Sudarshan Sharma, Michael A Gold, Lisa Landrum, C. Mathews, Grace Antony, S. Stevens, M. Powell, M. Mirza
{"title":"462 在ENGOT-EN6-NSGO/GOG-3031/RUBY试验中,与单纯化疗相比,多司他单抗联合化疗治疗原发性晚期/复发性子宫内膜癌患者的无进展生存期2-无进展生存期1","authors":"C. Mccourt, G. Ronzino, M. Shahin, Rebecca Kristeleit, L. Willmott, Oleksandr Zub, J. Barlin, L. Gilbert, N. Cloven, Line Bjørge, D. Black, M. Wymenga, Sudarshan Sharma, Michael A Gold, Lisa Landrum, C. Mathews, Grace Antony, S. Stevens, M. Powell, M. Mirza","doi":"10.1136/ijgc-2024-esgo.25","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"62 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"462 Progression-free survival 2-progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial\",\"authors\":\"C. Mccourt, G. Ronzino, M. Shahin, Rebecca Kristeleit, L. Willmott, Oleksandr Zub, J. Barlin, L. Gilbert, N. Cloven, Line Bjørge, D. Black, M. Wymenga, Sudarshan Sharma, Michael A Gold, Lisa Landrum, C. Mathews, Grace Antony, S. Stevens, M. Powell, M. Mirza\",\"doi\":\"10.1136/ijgc-2024-esgo.25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"62 10\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.25\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
462 Progression-free survival 2-progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
599 Modified minimally invasive versus open radical hysterectomy in early-stage cervical cancer: interim analysis of a multicenter, prospective, randomized controlled clinical trial 159 Peritonectomy and resection of mesentery during visceral-peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer: a phase I-II trial 849 Risk-reducing prophylactic fimbriectomy followed by delayed ooforectomy in women at risk of ovarian cancer: results of a single-center retrospective analysis 523 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of AtTEnd/ENGOT-EN7 trial 521 Safety and efficacy of Durvalumab (D) + Tremelimumab (T) + Metronomic Oral Vinorelbine (MOV) in patients with recurrent/metastatic cervical cancer (RMCC) in the MOVIE trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1